Trial Profile
Effects of rasagiline on cognitive function in patients with Parkinson's disease and mild cognitive impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Rasagiline (Primary)
- Indications Cognition disorders; Parkinson's disease
- Focus Therapeutic Use
- 03 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology